Researchers Suggest More Care In Using Abbott’s MitraClip

New data aggregated from over 5,000 reported adverse events suggests that patients should be aware of risks using MitraClip for TEER and operators should take more caution in handling the device.

A concept image of the MitraClip system as seen through x-ray • Source: Shutterstock

Researchers advise caution when using Abbott’s MitraClip device during transcatheter edge-to-edge repair (TEER) procedures, a new study of over 5,000 adverse event reports concludes.

The paper was published 18 January in JACC: Cardiovascular Interventions. Researchers explored national MitraClip outcomes through the US Food and Drug Administration’s

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Regulation

More from Policy & Regulation

UK Medtech Regulators Must Ensure Certainty So Businesses Can Plan Their Futures

 
• By 

With medtech businesses typically managing investment cycles on a three- to five-year basis, local regulatory processes and forward costs of market entry must offer an attractive environment in which companies can plan for growth, says McDermott Will and Emery’s partner and head of healthcare and life sciences, Sharon Lamb. Broad-scale improvements to NICE’s evaluation offerings would similarly enhance the UK’s value to innovators.

First At-Home Cervical Cancer Screening Tool Gets FDA Clearance

 
• By 

The US FDA has approved the Teal Wand, the first at-home cervical cancer screening device. Capable of detecting preclinical cancer with 96% accuracy, it will launch in California in June and expand nationwide soon after.

SS Innovations Files For De Novo For SSi Mantra 3 Surgical Robotic System For Multispecialty Indications

 
• By 

SS Innovations announced plans to file a de novo application with the US FDA for its SSi Mantra 3 surgical robot, already approved for marketing in six countries. The Florida-based firm also plans to pursue the CE mark for European commercialization.